Abbvie Inc. vs DexCom, Inc.
ABBV vs DXCM — side-by-side comparison from reported financials. ABBV leads 3, DXCM leads 8 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
DexCom, Inc.
DXCM · Healthcare
$84.11-0.36%Strong
| Metric | ABBV | DXCM |
|---|---|---|
| Price | $276.43 | $84.11 |
| Market cap | $488B | $31.7B |
| Revenue (TTM) | $64.4B | $4.97B |
| Revenue growth | +1.8% | +17.0% |
| Net margin | 9.8% | 20.1% |
| Free cash flow | $18.2B | $1.41B |
| Net cash (debt) | ($56.2B) | ($479M) |
| 1-year price return | +19.8% | +23.5% |
| P/E | 77.4 | 31.7 |
| P/E vs own history (cheap-side %) | 23% | 93% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 36% |
| Altman Z-score | 2.33 | 6.78 |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 11,100 |
Full résumé-style profiles: ABBV CV · DXCM CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.